First Gene Therapy Approved for Rare Glycogen Storage Disorder

The US Food and Drug Administration has approved the first gene therapy for glycogen storage disease type Ia, an ultra-rare inherited metabolic disorder.

The condition prevents the liver from releasing glucose normally, creating dangerous blood-sugar instability and long-term complications. Ultragenyx’s treatment, branded Genglycos, is authorised for adult and paediatric patients.

The approval represents an important scientific milestone, but access, long-term monitoring and cost will determine its practical reach. Rare-disease therapies require robust follow-up because benefits and risks can unfold over many years.

Reporting basis: NewsRena Editorial Desk review of reporting by Reuters.